Title:
PHARMACEUTICAL COMPOSITION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/093663
Kind Code:
A1
Abstract:
The present disclosure provides a pharmaceutical composition containing a therapeutically effective amount of furmonertinib or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, and use of furmonertinib or a pharmaceutically acceptable salt thereof, or said pharmaceutical composition in manufacture of a medicament for treating and/or preventing a disease mediated by HER2 exon 20 insertion mutation and/or EGFR rare mutation. The pharmaceutical composition of the present disclosure shows an excellent therapeutic effect on disease mediated by HER2 exon 20 insertion mutation and/or EGFR rare mutation (for example, non-small cell lung cancer (NSCLC) ) with little side effects and excellent safety.
Inventors:
LUO HUIBING (CN)
LI QING (CN)
LI QING (CN)
Application Number:
PCT/CN2022/133171
Publication Date:
June 01, 2023
Filing Date:
November 21, 2022
Export Citation:
Assignee:
SHANGHAI ALLIST PHARMACEUTICALS CO LTD (CN)
International Classes:
A61P35/00; A61K31/506; A61P35/04
Domestic Patent References:
| WO2021133809A1 | 2021-07-01 |
Foreign References:
| CN105315259A | 2016-02-10 |
Other References:
HAN B., ZHOU C., WU L., YU X., LI Q., LIU F., SHEN C.: "1210P Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)", vol. 32, 1 September 2021 (2021-09-01), pages S964, XP093046318, DOI: 10.1016/j.annonc.2021.08.1815
"CLINICALTRIALS.GOV.", 6 January 2020, CLASSIC.CLINICALTRIALS.GOV, US, article ALLIST PHARMACEUTICALS, INC: "Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer", pages: 1 - 4, XP093068407
" CLINICALTRIALS.GOV", 30 August 2021, CLASSIC.CLINICALTRIALS.GOV, US, article ALLIST PHARMACEUTICALS, INC: "Phase Ib Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation", pages: 1 - 3, XP093068409
ZHANG SHANNON S, OU SAI-HONG IGNATIUS: "Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?", LUNG CANCER: TARGETS AND THERAPY, vol. Volume 13, pages 67 - 73, XP093068410, DOI: 10.2147/LCTT.S385437
"CLINICALTRIALS.GOV.", 6 January 2020, CLASSIC.CLINICALTRIALS.GOV, US, article ALLIST PHARMACEUTICALS, INC: "Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer", pages: 1 - 4, XP093068407
" CLINICALTRIALS.GOV", 30 August 2021, CLASSIC.CLINICALTRIALS.GOV, US, article ALLIST PHARMACEUTICALS, INC: "Phase Ib Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation", pages: 1 - 3, XP093068409
ZHANG SHANNON S, OU SAI-HONG IGNATIUS: "Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?", LUNG CANCER: TARGETS AND THERAPY, vol. Volume 13, pages 67 - 73, XP093068410, DOI: 10.2147/LCTT.S385437
Attorney, Agent or Firm:
CHINA PATENT AGENT (H.K.) LTD. (CN)
Download PDF: